EyePoint Pharmaceuticals Inc
EYPT11.210USD
+0.130+1.17%
Handelsschluss 11/07, 16:00（ET）Kurse um 15 Minuten verzögert
779.88MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über EyePoint Pharmaceuticals Inc Unternehmen
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.
EyePoint Pharmaceuticals Inc Informationen
BörsenkürzelEYPT
Name des UnternehmensEyePoint Pharmaceuticals Inc
IPO-datumJan 27, 2005
CEODr. Jay S. Duker, M.D.
Anzahl der mitarbeiter165
WertpapierartOrdinary Share
GeschäftsjahresendeJan 27
Addresse480 Pleasant Street, Suite C400
StadtWATERTOWN
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl02472
Telefon16179265000
Websitehttps://eyepointpharma.com/
BörsenkürzelEYPT
IPO-datumJan 27, 2005
CEODr. Jay S. Duker, M.D.
Führungskräfte von EyePoint Pharmaceuticals Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Mr. Ramiro Ribeiro, M.D., Ph.D.
Mr. Ramiro Ribeiro, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
41.78K
--
Dr. Reginald J Sanders, M.D.
Dr. Reginald J Sanders, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Fred Hassan
Mr. Fred Hassan
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Stern
Mr. Stern
Investor Relations
Investor Relations
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Jay S. Duker, M.D.
Dr. Jay S. Duker, M.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
685.61K
+1.33%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Executive Vice Chairman of the Board
Executive Vice Chairman of the Board
575.46K
+1.97%
Dr. John B. Landis, Ph.D.
Dr. John B. Landis, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
142.86K
+567.59%
Ms. Karen L. Zaderej
Ms. Karen L. Zaderej
Non-Executive Independent Director
Non-Executive Independent Director
117.28K
+1.73%
Ms. Wendy F. Dicicco, CPA
Ms. Wendy F. Dicicco, CPA
Non-Executive Independent Director
Non-Executive Independent Director
107.43K
+977.87%
Mr. Stuart Duty
Mr. Stuart Duty
Non-Executive Independent Director
Non-Executive Independent Director
45.01K
--
Umsatzaufteilung
Währung: USDAktualisiert: Mon, Oct 6
Währung: USDAktualisiert: Mon, Oct 6
FY2024
FY2023
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
YUTIQ
3.10M
7.16%
Nach RegionUSD
Name
Umsatz
Anteil
United States
42.05M
97.17%
China
1.12M
2.60%
United Kingdom
100.00K
0.23%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
YUTIQ
3.10M
7.16%
Aktionärsstatistik
Aktualisiert: Sat, Aug 16
Aktualisiert: Sat, Aug 16
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
Cormorant Asset Management, LP
10.06%
Suvretta Capital Management, LLC
8.22%
Adage Capital Management, L.P.
8.21%
BlackRock Institutional Trust Company, N.A.
5.56%
Franklin Advisers, Inc.
5.15%
Andere
62.80%
Aktionäre
Aktionäre
Anteil
Cormorant Asset Management, LP
10.06%
Suvretta Capital Management, LLC
8.22%
Adage Capital Management, L.P.
8.21%
BlackRock Institutional Trust Company, N.A.
5.56%
Franklin Advisers, Inc.
5.15%
Andere
62.80%
Aktionärstypen
Aktionäre
Anteil
Hedge Fund
33.33%
Investment Advisor
23.07%
Investment Advisor/Hedge Fund
20.71%
Research Firm
3.68%
Individual Investor
2.96%
Venture Capital
2.92%
Private Equity
1.68%
Bank and Trust
0.95%
Pension Fund
0.14%
Andere
10.56%
Institutionelle Beteiligung
Aktualisiert: Wed, Oct 1
Aktualisiert: Wed, Oct 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q3
378
69.28M
83.75%
-19.64M
2025Q2
385
78.45M
113.85%
-10.49M
2025Q1
386
76.27M
110.90%
-11.90M
2024Q4
373
75.75M
111.39%
+202.32K
2024Q3
358
60.55M
112.89%
-8.01M
2024Q2
345
60.80M
116.35%
-2.75M
2024Q1
328
57.32M
114.97%
+528.95K
2023Q4
282
52.72M
108.16%
+11.49M
2023Q3
239
37.39M
106.16%
-1.26M
2023Q2
224
35.30M
102.90%
-4.83M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
Cormorant Asset Management, LP
8.32M
12.08%
--
--
Jun 30, 2025
Suvretta Capital Management, LLC
6.80M
9.87%
--
--
Jun 30, 2025
Adage Capital Management, L.P.
6.80M
9.87%
+600.00K
+9.68%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
4.60M
6.67%
-346.31K
-7.00%
Jun 30, 2025
Franklin Advisers, Inc.
4.27M
6.19%
+148.48K
+3.60%
Jun 30, 2025
The Vanguard Group, Inc.
3.80M
5.52%
-15.98K
-0.42%
Jun 30, 2025
Federated Hermes Global Investment Management Corp.
3.58M
5.2%
-128.17K
-3.45%
Jun 30, 2025
TCG Crossover Management, LLC
3.57M
5.18%
--
--
Jun 30, 2025
Citadel Advisors LLC
2.34M
3.4%
+58.12K
+2.54%
Jun 30, 2025
Geode Capital Management, L.L.C.
1.59M
2.31%
-982.00
-0.06%
Jun 30, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Thu, Nov 6
Aktualisiert: Thu, Nov 6
Name
Anteil
Virtus LifeSci Biotech Clinical Trials ETF
1.16%
Simplify Health Care ETF
1.02%
SPDR S&P Pharmaceuticals ETF
0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.73%
Invesco Dorsey Wright SmallCap Momentum ETF
0.39%
Federated Hermes MDT Small Cap Core ETF
0.3%
iShares Micro-Cap ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.1%
Vanguard US Momentum Factor ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.1%
Mehr Anzeigen
Virtus LifeSci Biotech Clinical Trials ETF
Anteil1.16%
Simplify Health Care ETF
Anteil1.02%
SPDR S&P Pharmaceuticals ETF
Anteil0.98%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Anteil0.73%
Invesco Dorsey Wright SmallCap Momentum ETF
Anteil0.39%
Federated Hermes MDT Small Cap Core ETF
Anteil0.3%
iShares Micro-Cap ETF
Anteil0.16%
Invesco Nasdaq Biotechnology ETF
Anteil0.1%
Vanguard US Momentum Factor ETF
Anteil0.1%
ProShares Ultra Nasdaq Biotechnology
Anteil0.1%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Datum
Art
Verhältnis
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
Dec 08, 2020
Merger
10→1
